Could Incyte’s Ruxolitinib Cream Effectively Treat Vitiligo?


Vitiligo is a chronic autoimmune disease. The immune system attacks the pigment-producing melanocyte cells causing loss of skin pigmentation. This causes a skin discoloration condition known as vitiligo. The immune system’s attack affects around 0.2% to 2.0% of the world’s population. There are currently no U.S. FDA or European EMA approved products for this condition. Initial vitiligo symptoms start before age 20 and remain for the rest of the patients’ lives. The condition is not life-threatening but causes extreme stress for the people with repulsive skin discoloration.   

Incyte in the NEWS

Leave a Reply